Dietary restriction inadequate, phosphate still high Calcichew®

Slides:



Advertisements
Similar presentations
Chronic Renal Failure in Cats: Can we Halt the Decline?
Advertisements

Hyperphosphataemia in chronic kidney disease Clinical case scenarios
Hyperphosphataemia in chronic kidney disease Clinical case scenarios
MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE PEDRAM.AHMADPOOR SHAHID BEHESHTI MEDICAL UNIVERSITY.
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
©2010 DaVita Inc. All rights reserved. 1 Nutrition and Kidney Disease Sara Colman, RD, CDE DaVita.com Nutrition Project Specialist.
Dietary Phosphorus Restriction for Control of PTH in CKD Guideline 4.1. Restriction of Dietary Phosphorus in Patients with CKD  Dietary phosphorus should.
A.O.Osp.Riuniti Marche Nord Presidio San Salvatore
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Management of hyperphosphataemia of chronic kidny disease Presented by Pharmacist/ Eman Youssif 1.
Mario Cozzolino, MD, PhD NUOVE ACQUISIZIONI NELLA TERAPIA DELL’IPERPARATIROIDISMO SECONDARIO IN DIALISI PERITONEALE XV CONVEGNO del Gruppo di Studio di.
Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research.
NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.
Phosphate Binders … Not Just for Breakfast Anymore by Aimee Henry, DTR Sodexo Dietetic Intern.
UK Renal Registry 9 th Annual Report 2006 Fig 9.1 Percentage of patients with serum phosphate
Home Haemodialysis in Wales An Evaluation of Nutritional Needs Harriet Williams Clinical Dietitian - Renal Lead, BCU.
CHAPTER 9: Chronic Kidney Disease – Mineral and Bone DisorderKok Lai Sun Ching Chen Hua Fan Kin Sing Rozina Ghazalli Liew Yew Fong Source: 21 st MDTR Report.
Acute and Chronic Renal Failure By Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Patient presenting with symptoms of constipation Identify causeIdentify cause. Consider disease, drugs, pregnancy, immobility, psychological problems Confirm.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Oral phosphate binders in patients with kidney failure
Volume 68, Pages S24-S28 (July 2005)
Oral Phosphate Binders in Patients with Kidney Failure
Volume 83, Issue 5, Pages (May 2013)
Algorithm for management of anemia of CKD in adults
Effect of a Non-Calcium-Based Phosphate Binder on Fibroblast Growth Factor 23 in Chronic Kidney Disease Nephron Clin Pract 2013;123: DOI: /
Multimorbidity and diabetes - what to do?
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.
Phase 3b Treatment-Naive
Formula Mass.
The ECHO Observational Study
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
HYPERPHOSPHAT EMIA Group 5. Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology.
Diseases of the Renal System
Chronic kidney disease and pre-dialysis
Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018
Gout Management.
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.
Renal Pharmacy Group Beginners Lectures 2018
Frederik Persson, Peter Rossing  Kidney International Supplements 
American Journal of Kidney Diseases 
Figure 7 The efficacy of phosphate-binder therapy
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Volume 63, Issue 6, Pages (June 2003)
Volume 64, Issue 6, Pages (December 2003)
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets  David M. Spiegel, Kate Brady  Kidney.
CHAPTER 9 Chronic Kidney Disease – Mineral and Bone Disorder
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials  Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,
Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients
Volume 66, Pages S25-S32 (September 2004)
Volume 83, Issue 5, Pages (May 2013)
Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C
Charles R. Nolan, Wajeh Y. Qunibi  Kidney International 
The calcium–phosphorus in guidelines for CKD-MBD
Volume 68, Pages S24-S28 (July 2005)
Volume 74, Pages S88-S93 (December 2008)
Conclusion and Future Direction:
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Methods for guideline development
Diseases of the Renal System
UK Renal Registry 14th Annual Report
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
Multimorbidity and diabetes - what to do?
Lanthanum pharmacokinetics: Are rat data misleading?
Effect of sevelamer versus calcium-based binders on all-cause mortality in patients with CKD. Compared with calcium-based binders (CBBs), sevelamer significantly.
Diseases of the Renal System
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials  Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,
Clinical Practice Guidelines for Peritoneal Dialysis Adequacy
Presentation transcript:

Treatment algorithm for control of hyperphosphataemia in adults with CKD Dietary restriction inadequate, phosphate still high Calcichew® (chewable calcium carbonate) 500 mg Ca2+ Max 3 tablets/24h First line: Osvaren® Calcium acetate/magnesium carbonate 110 mg Ca2+ Maximum 12 tablets / 24 hours Low Ca2+ High Mg2+ Osvaren dose optimised Check concordance Phosphate still high Calcium high Target ranges: CKD stage (3- 5 pre-dialysis) Phosphate: 0.8 to 1.5 mmol/l C. Calcium: 2.1 to 2.5 mmol/l CKD stage 5 (on dialysis) Phosphate: 1.1 to 1.7 mmol/l Sevelamer (Renvela®) 2.4 – 4.8g / 24hours Tablet or sachet Lanthanum (Fosrenol®) 1.5g – 3g / 24 hours Chewable / sachet NICE Clinical guideline CG157 - Hyperphosphataemia in Chronic kidney disease March 2013